Resolution of the Expert Council “New approaches to the treatment of axial spondyloarthritis”

On 30 May, 2024, an expert meeting was held to update the approaches for the treatment of axial spondyloarthritis (axSpA). A new approach to the treatment of axSpA was considered, which consists of depleting autoreactive TRBV9+ T- lymphocytes by introducing a monoclonal antibody – the drug seniprutu...

Full description

Saved in:
Bibliographic Details
Published inSovremennai͡a︡ revmatologii͡a Vol. 18; no. 3; pp. 134 - 139
Main Authors A. M. Lila, V. I. Mazurov, E. L. Nasonov, S. A. Lukyanov, T. V. Dubinina, I. Z. Gaidukova, A. A. Klimenko, S. A. Lapshina, G. V. Lukina, M. A. Korolev, R. O. Dreval, P. I. Pchelnikova, N. V. Shatalova
Format Journal Article
LanguageRussian
Published IMA-PRESS LLC 01.06.2024
Subjects
axial spondyloarthritis
seniprutug
treatment
Online AccessGet full text

Cover

More Information
Summary:On 30 May, 2024, an expert meeting was held to update the approaches for the treatment of axial spondyloarthritis (axSpA). A new approach to the treatment of axSpA was considered, which consists of depleting autoreactive TRBV9+ T- lymphocytes by introducing a monoclonal antibody – the drug seniprutug. The value of the drug seniprutug in the treatment of the disease was discussed and key aspects for the incorporation of the drug seniprutug into real-world clinical rheumatological practice were agreed.
ISSN:1996-7012
2310-158X
DOI:10.14412/1996-7012-2024-3-134-139